Olodanrigan

DB16266InvestigationalSmall molecule

Olodanrigan is under investigation in clinical trial NCT03297294 (Safety and Efficacy of EMA401 in Patients With Painful Diabetic Neuropathy (PDN)).

Mechanism: Pharmacologically active on Type-2 angiotensin II receptor
Curator reviewed
Formula / weight: C₃₂H₂₉NO₅ · 507.586 g/mol (avg)
Code names: EMA-401 · PD-126055

Resolves to

Compound

Structure

InChIKeyGHBCIXGRCZIPNQ-MHZLTWQESA-NSMILESCOC1=CC=C2CN([C@@H](CC2=C1OCC1=CC=CC=C1)C(O)=O)C(=O)C(C1=CC=CC=C1)C1=CC=CC=C1

Targets

What you can answer from here — as of May 04, 2022

1Protein targetEach mapped to UniProt, with action and pharmacological action

Listed above

4Clinical trialsPhase, status and sponsor resolved per trial

7+ReferencesStructured and connected to the statements they support

Which drugs share a target with Olodanrigan, and which of those have an active Phase 3 trial?

Create a free account or log in to explore the full data card.